| Symbol | ENTA |
|---|---|
| Name | ENANTA PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 4 KINGSBURY AVENUE, WATERTOWN, MA 02472 |
| Telephone | 617 607 0800 |
| Fax | — |
| — | |
| Website | https://www.enanta.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001177648 |
| Description | Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The companys inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. Additional info from NASDAQ: |
2026-05-04 11:00
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026
Read more
2026-04-07 11:00
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Read more
2026-03-30 11:00
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Read more
2026-03-26 19:07
New Form SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-001192 <b>Size:</b> 7 KB
Read more
2026-03-26 12:00
(99% Neutral) ENANTA PHARMACEUTICALS INC (ENTA) Announces Update on Collaboration with Common Stock
Read more
2026-03-13 20:20
Director Vance Terry 🟢 acquired 20.0K shares (1 derivative) of ENANTA PHARMACEUTICALS INC (ENTA) at $14.17 Transaction Date: Mar 11, 2026 | Filing ID: 000143
Read more
2026-03-13 20:19
Director Russell Lesley 🟢 acquired 20.0K shares (1 derivative) of ENANTA PHARMACEUTICALS INC (ENTA) at $14.17 Transaction Date: Mar 11, 2026 | Filing ID: 000142
Read more
2026-03-13 20:18
Director Peterson Kristine 🟢 acquired 20.0K shares (1 derivative) of ENANTA PHARMACEUTICALS INC (ENTA) at $14.17 Transaction Date: Mar 11, 2026 | Filing ID: 000141
Read more
2026-03-13 20:17
Director Hata Yujiro S 🟢 acquired 20.0K shares (1 derivative) of ENANTA PHARMACEUTICALS INC (ENTA) at $14.17 Transaction Date: Mar 11, 2026 | Filing ID: 000140
Read more
2026-03-13 20:15
Director FOLETTA MARK G 🟢 acquired 20.0K shares (1 derivative) of ENANTA PHARMACEUTICALS INC (ENTA) at $14.17 Transaction Date: Mar 11, 2026 | Filing ID: 000139
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT00989872 | Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfas… | Phase1 | Skin and Soft Tissue Infections | Completed | — | — | ClinicalTrials.gov |
| NCT07482657 | A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Partic… | Phase2 | RSV Infection | Not_Yet_Recruiting | 2026-07-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT07540910 | A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmaco… | Phase1 | Chronic Inducible Urticaria | Recruiting | 2026-04-01 | 2026-11-01 | ClinicalTrials.gov |
| NCT06917508 | A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffei… | Phase1 | RSV Infection | Completed | 2025-03-13 | 2025-06-13 | ClinicalTrials.gov |
| NCT06847464 | A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamaz… | Phase1 | RSV Infection | Completed | 2025-01-27 | 2025-06-01 | ClinicalTrials.gov |
| NCT06601192 | A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in … | Phase1 | RSV Infection | Completed | 2024-07-15 | 2025-02-25 | ClinicalTrials.gov |
| NCT06170242 | A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respira… | Phase2 | RSV Infection | Completed | 2023-11-20 | 2024-07-12 | ClinicalTrials.gov |
| NCT05568706 | A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for… | Phase2 | RSV Infection | Completed | 2022-11-29 | 2025-06-23 | ClinicalTrials.gov |
| NCT05616728 | A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19 | Phase2 | COVID-19 | Completed | 2022-11-10 | 2023-06-29 | ClinicalTrials.gov |
| NCT05594602 | Drug-Drug Interaction Study Between EDP-235, Itraconazole, Carbamazepine and Qu… | Phase1 | COVID-19 | Completed | 2022-10-06 | 2022-12-30 | ClinicalTrials.gov |
| NCT05594615 | Drug-Drug Interaction Study Between EDP-235, Midazolam, Caffeine and Rosuvastat… | Phase1 | COVID-19 | Completed | 2022-10-06 | 2022-11-18 | ClinicalTrials.gov |
| NCT05587478 | A Study of EDP-323 in Healthy Subjects | Phase1 | RSV Infection | Completed | 2022-09-29 | 2023-03-29 | ClinicalTrials.gov |
| NCT04816721 | A Study to Evaluate EDP 938 Regimens in Children With RSV | Phase2 | Respiratory Syncytial Virus (RSV) | Completed | 2022-04-26 | 2024-08-19 | ClinicalTrials.gov |
| NCT05246878 | A Study of EDP-235 in Healthy Subjects | Phase1 | SARS CoV 2 Infection | Completed | 2022-01-28 | 2022-07-20 | ClinicalTrials.gov |
| NCT04971512 | A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATIO… | Phase1 | Chronic Hepatitis B Virus Infection | Terminated | 2021-08-02 | 2021-12-20 | ClinicalTrials.gov |
| NCT04633187 | Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Re… | Phase2 | Respiratory Syncytial Virus Infections | Terminated | 2021-07-07 | 2023-05-31 | ClinicalTrials.gov |
| NCT04927793 | Absorption, Metabolism, and Excretion (AME) Study of [14C]EDP-938 in Healthy Ma… | Phase1 | Respiratory Syncytial Virus (RSV) | Completed | 2021-05-28 | 2021-07-04 | ClinicalTrials.gov |
| NCT04871724 | Drug-Drug Interaction Study Between Fluconazole and EDP-938 in Healthy Subjects | Phase1 | RSV Infection | Completed | 2021-03-12 | 2021-04-16 | ClinicalTrials.gov |
| NCT04783753 | Drug-Drug Interaction Study Between EDP-514, Itraconazole, Carbamazepine, and Q… | Phase1 | Hepatitis B | Completed | 2020-11-05 | 2021-07-09 | ClinicalTrials.gov |
| NCT04470388 | A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are… | Phase1 | Chronic HBV Infection | Completed | 2020-09-09 | 2021-08-30 | ClinicalTrials.gov |
| NCT04559126 | A Study of EDP-297 in Healthy Subjects | Phase1 | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | Completed | 2020-09-08 | 2021-06-21 | ClinicalTrials.gov |
| NCT04498741 | Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastat… | Phase1 | RSV Infection | Completed | 2020-07-08 | 2021-06-01 | ClinicalTrials.gov |
| NCT04378010 | A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 i… | Phase2 | Non-Alcoholic Steatohepatitis | Terminated | 2020-01-27 | 2021-11-30 | ClinicalTrials.gov |
| NCT04196101 | A Study to Assess EDP-938 for the Treatment of Acute Upper Respiratory Tract In… | Phase2 | Respiratory Syncytial Virus | Completed | 2020-01-22 | 2022-01-04 | ClinicalTrials.gov |
| NCT04008004 | A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepat… | Phase1 | Chronic HBV Infection | Completed | 2019-06-26 | 2021-07-14 | ClinicalTrials.gov |
| NCT03755778 | Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinid… | Phase1 | RSV Infection | Completed | 2018-11-29 | 2019-01-27 | ClinicalTrials.gov |
| NCT03783897 | A Drug-drug Interaction Study to Investigate the Effect of Coadministration of … | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2018-11-27 | 2019-06-18 | ClinicalTrials.gov |
| NCT03750383 | Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Hea… | Phase1 | RSV Infection | Completed | 2018-11-02 | 2018-12-13 | ClinicalTrials.gov |
| NCT03691623 | A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model | Phase2 | RSV Infection | Completed | 2018-10-15 | 2019-10-18 | ClinicalTrials.gov |
| NCT03748628 | Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Mal… | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2018-10-05 | 2018-10-13 | ClinicalTrials.gov |
| NCT03610945 | Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healt… | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2018-07-19 | 2018-08-21 | ClinicalTrials.gov |
| NCT03421431 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of ED… | Phase2 | Non-Alcoholic Steatohepatitis | Completed | 2018-04-25 | 2019-07-10 | ClinicalTrials.gov |
| NCT03394924 | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of ED… | Phase2 | Primary Biliary Cholangitis | Completed | 2017-12-27 | 2020-01-16 | ClinicalTrials.gov |
| NCT03384823 | A Study of EDP-938 in Healthy Subjects | Phase1 | RSV Infection | Completed | 2017-12-07 | 2018-07-03 | ClinicalTrials.gov |
| NCT03213145 | Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Heal… | Phase1 | NASH - Nonalcoholic Steatohepatitis | Completed | 2017-07-11 | 2017-09-07 | ClinicalTrials.gov |
| NCT03207425 | A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compar… | Phase1 | NASH | Completed | 2017-06-14 | 2017-09-19 | ClinicalTrials.gov |
| NCT03187496 | Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastat… | Phase1 | NASH | Completed | 2017-05-11 | 2017-06-14 | ClinicalTrials.gov |
| NCT02918929 | A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD | Phase1 | Presumptive NAFLD | Completed | 2016-09-01 | 2017-06-01 | ClinicalTrials.gov |
| NCT02652377 | EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients | Phase1 | Hepatitis C | Completed | 2016-01-10 | 2016-12-27 | ClinicalTrials.gov |
| NCT02173574 | Two-way Interaction Between Alisporivir and EDP239 | Phase1 | Hepatitis C Virus | Completed | 2014-08-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02255968 | Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral D… | Phase1 | Healthy | Terminated | 2014-08-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01999725 | Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788 | Phase1 | Safety in Normal Volunteers | Completed | 2014-01-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT01856426 | Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects | Phase1 | Hepatitis C | Completed | 2013-06-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT00990145 | Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers | Phase1 | MRSA, SSTI | Completed | 2008-11-01 | 2009-09-01 | ClinicalTrials.gov |
| NCT00270517 | Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Comm… | Phase2 | Community Acquired Pneumonia | Unknown | 2005-12-01 | 2007-07-01 | ClinicalTrials.gov |
Total clinical trials: 45
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| EDP-322 | Other | Phase PHASE1 | Skin and Soft Tissue Infections | COMPLETED | NCT00989872 |
| Quinidine | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03755778 |
| Rifampin | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03755778 |
| Itraconazole | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03755778 |
| EDP-938 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03755778 |
| EDP-938 | Other | Phase PHASE1 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT04927793 |
| EDP-322 | Other | Phase PHASE1 | MRSA, SSTI | COMPLETED | NCT00990145 |
| EDP239 | Other | Phase PHASE1 | Hepatitis C Virus | COMPLETED | NCT02173574 |
| DEB025 | Other | Phase PHASE1 | Hepatitis C Virus | COMPLETED | NCT02173574 |
| Placebo | Other | Phase PHASE1 | Safety in Normal Volunteers | COMPLETED | NCT01999725 |
| EDP-788 | Other | Phase PHASE1 | Safety in Normal Volunteers | COMPLETED | NCT01999725 |
| Placebo | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02255968 |
| EDP-788 | Other | Phase PHASE1 | Healthy | TERMINATED | NCT02255968 |
| Placebo | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01856426 |
| EDP239 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT01856426 |
| Placebo | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02652377 |
| EDP-494 | Other | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02652377 |
| EDP-305 | Other | Phase PHASE1 | NASH | COMPLETED | NCT03187496 |
| Rosuvastatin | Other | Phase PHASE1 | NASH | COMPLETED | NCT03187496 |
| Caffeine | Other | Phase PHASE1 | NASH | COMPLETED | NCT03187496 |
| Midazolam | Other | Phase PHASE1 | NASH | COMPLETED | NCT03187496 |
| Placebo | Other | Phase PHASE1 | Presumptive NAFLD | COMPLETED | NCT02918929 |
| EDP 305 | Other | Phase PHASE1 | Presumptive NAFLD | COMPLETED | NCT02918929 |
| EDP 305 | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03213145 |
| Rifampin | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03213145 |
| intraconazole | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03213145 |
| EDP 305 | Other | Phase PHASE1 | NASH | COMPLETED | NCT03207425 |
| Placebo | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03384823 |
| EDP-938 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03384823 |
| EDP-305 | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03748628 |
| EDP-305 | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03610945 |
| Quinidine | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03610945 |
| Fluconazole | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03610945 |
| Prednisone | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03750383 |
| Cyclosporine | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03750383 |
| EDP-938 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT03750383 |
| Oral Contraceptive | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03783897 |
| EDP-305 | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03783897 |
| Fluconazole | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04871724 |
| EDP-938 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04871724 |
| Placebo | Other | Phase PHASE2 | Primary Biliary Cholangitis | COMPLETED | NCT03394924 |
| EDP-305 2.5 mg | Other | Phase PHASE2 | Primary Biliary Cholangitis | COMPLETED | NCT03394924 |
| EDP-305 1 mg | Other | Phase PHASE2 | Primary Biliary Cholangitis | COMPLETED | NCT03394924 |
| Quinidine | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04783753 |
| Carbamazepin | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04783753 |
| Itraconazole | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04783753 |
| EDP-514 | Other | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04783753 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT03421431 |
| EDP-305 Dose 2 | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT03421431 |
| EDP-305 Dose 1 | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT03421431 |
| Midazolam | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| Rosuvastatin | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| Dabigatran | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| Tacrolimus | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| EDP-938 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| Placebo | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | COMPLETED | NCT04559126 |
| EDP-297 | Other | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | COMPLETED | NCT04559126 |
| Placebo | Other | Phase PHASE1 | Chronic HBV Infection | COMPLETED | NCT04470388 |
| EDP-514 | Other | Phase PHASE1 | Chronic HBV Infection | COMPLETED | NCT04470388 |
| Placebo | Other | Phase PHASE1 | Chronic HBV Infection | COMPLETED | NCT04008004 |
| EDP-514 | Other | Phase PHASE1 | Chronic HBV Infection | COMPLETED | NCT04008004 |
| EDP-514 | Other | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| Placebo (Part 2) | Other | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| EDP-721 (Part 2) | Other | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| Placebo (Part 1) | Other | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| EDP-721 | Other | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| EDP-938 Dose 4 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| EDP-938 Dose 3 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| Placebo | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| EDP-938 Dose 2 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| EDP-938 Dose 1 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| Placebo | Other | Phase PHASE1 | SARS CoV 2 Infection | COMPLETED | NCT05246878 |
| EDP-235 | Other | Phase PHASE1 | SARS CoV 2 Infection | COMPLETED | NCT05246878 |
| Caffeine | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594615 |
| Rosuvastatin | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594615 |
| Midazolam | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594615 |
| EDP-235 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594615 |
| Quinidine | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594602 |
| Carbamazepine | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594602 |
| Itraconazole | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594602 |
| EDP-235 | Other | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594602 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT04378010 |
| EDP-305 2 mg | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT04378010 |
| EDP-305 1.5 mg | Other | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT04378010 |
| Placebo | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT05587478 |
| EDP-323 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT05587478 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT04196101 |
| EDP-938 | Other | Phase PHASE2 | Respiratory Syncytial Virus | COMPLETED | NCT04196101 |
| Placebo | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT05616728 |
| EDP-235 | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT05616728 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04633187 |
| EDP-938 | Other | Phase PHASE2 | Respiratory Syncytial Virus Infections | TERMINATED | NCT04633187 |
| Rosuvastatin | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| Caffeine | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| Midazolam | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| EDP-323 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| fluconazole | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| Quinidine | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| carbamazepine | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| Itraconazole | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| EDP-323 | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| Placebo | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT05568706 |
| EDP-938 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT05568706 |
| moxifloxacin | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| Placebo | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| zelicapavir (supratherapeutic dose) | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| zelicapavir (therapeutic dose) | Other | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| Placebo | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT04816721 |
| EDP-938 | Other | Phase PHASE2 | Respiratory Syncytial Virus (RSV) | COMPLETED | NCT04816721 |
| Placebo | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT06170242 |
| EDP-323 Dose Regimen 2 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT06170242 |
| EDP-323 Dose Regimen 1 | Other | Phase PHASE2 | RSV Infection | COMPLETED | NCT06170242 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| Placebo | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EDP-978 | Other | Phase PHASE1 | Chronic Inducible Urticaria | RECRUITING | NCT07540910 |
| EU-Sourced Orencia® | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02923583 |
| US-Sourced Orencia® | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02923583 |
| M834 | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02923583 |
| Autoinjector | DEVICE | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02722044 |
| Necuparanib | DRUG | Phase PHASE1 | Metastatic Pancreatic Cancer | TERMINATED | NCT01621243 |
| placebo | DRUG | Phase PHASE1 | Metastatic Pancreatic Cancer | TERMINATED | NCT01621243 |
| gemcitabine | DRUG | Phase PHASE1 | Metastatic Pancreatic Cancer | TERMINATED | NCT01621243 |
| nab-paclitaxel | DRUG | Phase PHASE1 | Metastatic Pancreatic Cancer | TERMINATED | NCT01621243 |
| Humira | BIOLOGICAL | Phase PHASE3 | Chronic Plaque Psoriasis | COMPLETED | NCT02581345 |
| M923 | BIOLOGICAL | Phase PHASE3 | Rheumatoid Arthritis | COMPLETED | NCT02722044 |
| Unfractionated Heparin | DRUG | Phase PHASE2 | Coronary Artery Disease (CAD) | COMPLETED | NCT00543400 |
| M118 | DRUG | Phase PHASE2 | Coronary Artery Disease (CAD) | COMPLETED | NCT00543400 |
| Long- and intermediate- acting insulins | DRUG | Preclinical | Diabetes | COMPLETED | NCT02922179 |
| Bardoxolone Methyl | DRUG | Phase PHASE2 | Covid19 | COMPLETED | NCT04494646 |
| M281 | BIOLOGICAL | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02828046 |
| TNF-α antagonists, non-TNFs, DMARD non-biologics | DRUG | Preclinical | Rheumatoid Arthritis | COMPLETED | NCT02922192 |
| filgrastim, TBO-filgrastim or pegfilgrastim | DRUG | Preclinical | Breast Cancer | COMPLETED | NCT02921191 |
| Intravenous immunoglobulin (IVIg) | BIOLOGICAL | Phase PHASE1 | Immune Thrombocytopenic Purpura (ITP) | TERMINATED | NCT03866577 |
| Biological: M254 | BIOLOGICAL | Phase PHASE1 | Immune Thrombocytopenic Purpura (ITP) | TERMINATED | NCT03866577 |
| zelicapavir | DRUG | Phase PHASE2 | RSV Infection | NOT_YET_RECRUITING | NCT07482657 |
| fluconazole | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| carbamazepine | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| moxifloxacin | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| zelicapavir (supratherapeutic dose) | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| zelicapavir (therapeutic dose) | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06601192 |
| EDP-323 Dose Regimen 2 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT06170242 |
| EDP-323 Dose Regimen 1 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT06170242 |
| Carbamazepine | DRUG | Phase PHASE1 | COVID-19 | COMPLETED | NCT05594602 |
| EDP-323 | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| EDP-235 | DRUG | Phase PHASE2 | COVID-19 | COMPLETED | NCT05616728 |
| Placebo (Part 2) | DRUG | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| EDP-721 (Part 2) | DRUG | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| Placebo (Part 1) | DRUG | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| EDP-721 | DRUG | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| Carbamazepin | DRUG | Phase PHASE1 | Hepatitis B | COMPLETED | NCT04783753 |
| EDP-297 | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis | COMPLETED | NCT04559126 |
| Dabigatran | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| Tacrolimus | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT04498741 |
| EDP-305 2 mg | DRUG | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT04378010 |
| EDP-305 1.5 mg | DRUG | Phase PHASE2 | Non-Alcoholic Steatohepatitis | TERMINATED | NCT04378010 |
| EDP-514 | DRUG | Phase PHASE1 | Chronic Hepatitis B Virus Infection | TERMINATED | NCT04971512 |
| Oral Contraceptive | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03783897 |
| Itraconazole | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| Prednisone | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT03750383 |
| Cyclosporine | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT03750383 |
| EDP-938 Dose 4 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| EDP-938 Dose 3 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| EDP-938 Dose 2 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| EDP-938 Dose 1 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT03691623 |
| Quinidine | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06847464 |
| Fluconazole | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT04871724 |
| EDP-305 Dose 2 | DRUG | Phase PHASE2 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT03421431 |
| EDP-305 Dose 1 | DRUG | Phase PHASE2 | Non-Alcoholic Steatohepatitis | COMPLETED | NCT03421431 |
| EDP-305 2.5 mg | DRUG | Phase PHASE2 | Primary Biliary Cholangitis | COMPLETED | NCT03394924 |
| EDP-305 1 mg | DRUG | Phase PHASE2 | Primary Biliary Cholangitis | COMPLETED | NCT03394924 |
| EDP-938 | DRUG | Phase PHASE2 | RSV Infection | COMPLETED | NCT05568706 |
| Rifampin | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT03755778 |
| intraconazole | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03213145 |
| EDP-305 | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03783897 |
| Rosuvastatin | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| Caffeine | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| Midazolam | DRUG | Phase PHASE1 | RSV Infection | COMPLETED | NCT06917508 |
| EDP 305 | DRUG | Phase PHASE1 | NASH - Nonalcoholic Steatohepatitis | COMPLETED | NCT03213145 |
| EDP-494 | DRUG | Phase PHASE1 | Hepatitis C | COMPLETED | NCT02652377 |
| EDP-788 | DRUG | Phase PHASE1 | Healthy | TERMINATED | NCT02255968 |
| DEB025 | DRUG | Phase PHASE1 | Hepatitis C Virus | COMPLETED | NCT02173574 |
| Placebo | OTHER | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02828046 |
| EDP239 | DRUG | Phase PHASE1 | Hepatitis C Virus | COMPLETED | NCT02173574 |
| EDP-322 | DRUG | Phase PHASE1 | MRSA, SSTI | COMPLETED | NCT00990145 |
| Telithromycin / Duration of Treatment - 7 days | DRUG | Phase PHASE2 | Community Acquired Pneumonia | UNKNOWN | NCT00270517 |
| EDP-420 / Duration of Treatment - 3 days | DRUG | Phase PHASE2 | Community Acquired Pneumonia | UNKNOWN | NCT00270517 |
Total products: 201